Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)
11th December 2020
Portfolio
This post references, or is about AtoxBio. Find out more by clicking below
Print Article
Email Article
Save Article
